Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine in Adults With ADHD and Comorbid Social Anxiety Disorder
NCT00190879Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), Social Anxiety Disorder (SAD), sponsored by Eli Lilly and Company. Started Jun 2005; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT00190879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00190879.